Modified Rv3616c Antigens for Latent TB Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current tuberculosis treatments and vaccines are inadequate for preventing latent infection and reactivation, with existing vaccines like BCG not effectively addressing latent TB or pulmonary disease reactivation, and new generation vaccines being less effective as post-exposure therapeutic options.
Innovation Solution
Modified Rv3616c proteins with disrupted hydrophobicity in specific regions, allowing for improved expression and immunogenicity, are used as antigens to induce an immune response and treat or prevent latent tuberculosis and its reactivation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If BCG vaccination is used to protect against severe disease manifestation in children, then protective immunity is induced, but it does not prevent the establishment of latent TB or reactivation of pulmonary disease in adult life
Solution Approach 1:
The invention modifies the Rv3616c protein by changing specific amino acid residues (K152E, R153E, R155E substitutions) to alter its immunogenic properties. These parameter changes in the antigen structure enable the vaccine to induce immunity that prevents both active disease and latent TB reactivation, overcoming the limitations of BCG
Solution Approach 2:
The vaccine comprises a composite approach by combining the modified Rv3616c protein with specific adjuvants (QS21, MPLA, or alum) and delivery systems (liposomes or nanoparticles). This composite formulation enhances the immune response to achieve broader protection including prevention of latent TB establishment and reactivation
2Reliability
If new generation TB vaccines are designed as pre-exposure vaccines to improve resistance to infection, then vaccination efficacy is enhanced, but they are likely to be less effective as post-exposure or therapeutic vaccines in latent TB cases
Solution Approach 1:
The modified Rv3616c protein vaccine is designed to serve multiple functions: it can be used as a pre-exposure prophylactic vaccine to prevent initial infection, as a post-exposure therapeutic to eliminate latent infection, and as a booster to enhance existing immunity. The protein's modified structure enables it to stimulate both naive and memory T cells, providing universal applicability across different vaccination scenarios
3Reliability
If extended antibiotic therapy is used to control tuberculosis, then active disease can be treated, but it is not sufficient to prevent the spread of the disease and may lead to drug resistance
Solution Approach 1:
The invention replaces the mechanical/chemical approach of extended antibiotic therapy with an immunological approach using modified protein vaccines. Instead of relying on antibiotics that select for resistant bacteria, the vaccine stimulates the host's immune system to naturally eliminate the bacteria, including dormant latent forms, thereby preventing both active disease and the development of drug resistance
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Modified Rv3616c proteins and their use as medicaments, particularly for the prevention of reactivation of tuberculosis.